C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics Stock Forecast

CCCC's stock price has decreased by -78.26% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 4 analysts with 12-month price forecasts for C4 Therapeutics stock have an average target of 12.5, with a low estimate of 4.00 and a high estimate of 20. The average target predicts an increase of 666.87% from the current stock price of 1.63.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$4.00	$12.5	$14	$20
Change	+145.40%	+666.87%	+758.90%	+1127.0%

* Price targets were last updated on Dec 19, 2024.

Analyst Ratings

The average analyst rating for C4 Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	2	1	1	1	1	1
Buy	1	1	2	2	2	2
Hold	4	4	3	3	3	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	6	6	6	6	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Derek Archila Wells Fargo	Wells Fargo	Hold → Buy Upgrades $8 → $12	Hold → Buy	Upgrades	$8 → $12	+636.20%	Dec 19, 2024
Sudan Loganathan Stephens & Co.	Stephens & Co.	Hold Initiates $4	Hold	Initiates	$4	+145.40%	Nov 18, 2024
Etzer Darout BMO Capital	BMO Capital	Buy Reiterates $20	Buy	Reiterates	$20	+1,126.99%	Aug 6, 2024
Derek Archila Wells Fargo	Wells Fargo	Hold Maintains $7 → $8	Hold	Maintains	$7 → $8	+390.80%	May 9, 2024
Bradley Canino Stifel	Stifel	Strong Buy Maintains $13 → $14	Strong Buy	Maintains	$13 → $14	+758.90%	May 9, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

21.92M

Decreased by -38.39%

from 35.58M

Revenue Next Year

29.89M

Increased by 36.32%

from 21.92M

EPS This Year

-1.93

from -1.52

EPS Next Year

-1.73

from -1.93

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	33.20M	45.79M	31.10M	20.76M	35.58M	21.92M	29.89M	19.86M
Revenue Growth	55.25%	37.93%	-32.08%	-33.25%	71.44%	-38.39%	36.32%	-33.56%
EPS	-5.83	-1.82	-2.62	-2.67	-1.52	-1.93	-1.73	-1.66
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	12	12	10

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	47.3M	118.7M	31.2M
Avg	21.9M	29.9M	19.9M
Low	n/a	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	32.8%	441.2%	4.4%
Avg	-38.4%	36.3%	-33.6%
Low	-	-	-

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-1.60	-0.90	-0.93
Avg	-1.93	-1.73	-1.66
Low	-2.33	-2.55	-2.49

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.